Drug Price Relief Within Reach as Washington Faces Mounting Pressure to Act

Americans continue to pay the highest prescription drug prices in the developed world, and a growing coalition of employers, patients, and policymakers is urging Congress and the White House to act on reforms that could deliver meaningful relief. With pharmacy benefit manager reform, price transparency measures, and Medicare negotiation expansion all on the table, analysts say the window for bipartisan action is narrowing ahead of the next election cycle.

The phrase popularized by longtime Democratic strategist James Carville during Bill Clinton’s 1992 presidential campaign — “It’s the economy, stupid” — continues to resonate more than three decades later as voters name inflation, housing, and health care costs among their top concerns. Prescription drug pricing sits at the intersection of those anxieties. Out-of-pocket spending on medications has climbed steadily, and employer-sponsored health plans, which cover roughly 153 million Americans, have absorbed double-digit percentage increases in specialty drug spending for several consecutive years. The result is a squeeze felt simultaneously by workers at the pharmacy counter and by the businesses that underwrite their benefits.

Much of the current policy debate centers on pharmacy benefit managers, the middlemen who negotiate rebates between drug manufacturers, insurers, and pharmacies. Critics, including the Federal Trade Commission in its July 2024 interim report, allege that PBMs use opaque pricing structures, steer patients toward affiliated pharmacies, and retain rebates that should theoretically lower consumer costs. PBM industry representatives counter that they save payers an estimated $145 billion annually and that eliminating rebates would simply shift costs elsewhere. Legislation such as the Pharmacy Benefit Manager Reform Act and the Modernizing and Ensuring PBM Accountability Act would require greater transparency, delink PBM compensation from list prices, and ban spread pricing in Medicaid.

Beyond PBM reform, several other proposals are circulating on Capitol Hill. These include expanding Medicare negotiation to a larger list of drugs, capping insulin costs for the commercially insured population (the IRA capped it only for Medicare beneficiaries at $35 per month), allowing the importation of certain medications from Canada, and accelerating generic and biosimilar competition. The Trump administration has also revived interest in a “most favored nation” pricing model that would tie certain Medicare drug payments to prices paid in peer countries — a proposal first floated during the president’s prior term and blocked by federal courts on procedural grounds. Whether any of these measures can advance depends on reconciling pharmaceutical industry opposition, which has historically deployed one of Washington’s largest lobbying operations, with voter demand for lower costs.